Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kaken Pharmaceutical Co (TSE:4521) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Kaken Pharmaceutical Co Forward PE Ratio Related Terms
Kaken Pharmaceutical Co Forward PE Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kaken Pharmaceutical Co Forward PE Ratio Chart
Kaken Pharmaceutical Co Annual Data
Trend
2025-03
2026-03
Forward PE Ratio
35.52
96.48
Kaken Pharmaceutical Co Quarterly Data
2024-12
2025-03
2025-06
2025-09
2025-12
2026-03
Forward PE Ratio
56.60
35.52
46.03
43.39
75.56
96.48
TSE:4521 vs ZTS: Forward PE Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Kaken Pharmaceutical Co's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kaken Pharmaceutical Co Forward PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kaken Pharmaceutical Co's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Kaken Pharmaceutical Co's Forward PE Ratio falls into.
Kaken Pharmaceutical Co Forward PE Ratio Calculation
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Kaken Pharmaceutical Co (TSE:4521) has a Forward PE Ratio of 20.99 as of Sep. 02, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Kaken Pharmaceutical Co and its competitors. According to the industry distribution chart, Kaken Pharmaceutical Co ranks #267 out of 412 companies in the Drug Manufacturers industry, placing it in the top 64.8%.
Is Kaken Pharmaceutical Co's Forward PE Ratio too high?
Kaken Pharmaceutical Co's current Forward PE Ratio is 20.99. The Drug Manufacturers industry median Forward PE Ratio is 14.81. Kaken Pharmaceutical Co's value of 20.99 is 41.8% above this industry median. Based on the distribution chart, Kaken Pharmaceutical Co ranks #267 out of 412 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Kaken Pharmaceutical Co has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Kaken Pharmaceutical Co's Forward PE Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Kaken Pharmaceutical Co ranks #267 out of 412 companies for Forward PE Ratio. This places Kaken Pharmaceutical Co in the lower half of its industry. The industry median Forward PE Ratio is 14.81. Kaken Pharmaceutical Co's value of 20.99 is 41.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Drug Manufacturers company?
The median Forward PE Ratio among Drug Manufacturers companies is 14.81, based on 412 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kaken Pharmaceutical Co's current Forward PE Ratio of 20.99 is 41.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Kaken Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Forward PE Ratio is 14.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kaken Pharmaceutical Co's current Forward PE Ratio is 20.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kaken Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Kaken Pharmaceutical Co (TSE:4521) is currently considered Fairly Valued. The stock's GF Value™ is 円4,009.08, compared to a current price of 円4,010.00 — trading 0% above its estimated fair value. The current Forward PE Ratio is 20.99 and 41.8% above the Drug Manufacturers industry median of 14.81. Kaken Pharmaceutical Co's overall GF Score™ is 61/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Kaken Pharmaceutical Co (TSE:4521), the current Forward PE Ratio is 20.99 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kaken Pharmaceutical Co (TSE:4521) Overvalued in 2026?
Based on GuruFocus' analysis, Kaken Pharmaceutical Co stock appears to be overvalued.
The current stock price of 円4,010.00 is trading 0% above its estimated GF Value™ of 円4,009.08.
GuruFocus considers Kaken Pharmaceutical Co to be Fairly Valued.
Key valuation signals for TSE:4521:
Forward PE Ratio: 20.99
GF Value™: 円4,009.08 vs. price of 円4,010.00 (0% above fair value)
Industry Position: 41.8% above the Drug Manufacturers median (#267 of 412)
No single metric tells the full story. See the TSE:4521 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kaken Pharmaceutical Co Ltd is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
61GF Score
Get the complete analysis for TSE:4521
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4521 has been successfully added to your 
